Concord Biotech Ltd
Concord Biotech Ltd (CONCORDBIO) last traded at ₹1,557, a market capitalisation of ₹16,285 crore, on a P/E of 58.7. Over the past 52 weeks the stock has ranged between ₹987 and ₹1,748. Concord Biotech Ltd last reported results for the quarter ended Jun 2026, with sales of ₹257 crore and net profit of ₹58 crore. The next scheduled event is an analyst meet on 26 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.
Concord Biotech Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Concord Biotech Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹257 cr, up 26.0% from ₹204 cr a year earlier. Net profit was ₹58 cr, up 31.8% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 257 |
| Expenses | 176 | 146 | 241 | 143 | 159 | 179 | 208 | 175 |
| Operating profit | 134 | 98 | 189 | 61 | 88 | 98 | 118 | 82 |
| OPM % | 43% | 40% | 44% | 30% | 36% | 35% | 36% | 32% |
| Other income | 10 | 17 | 9 | 15 | 16 | 7 | 15 | 14 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 13 | 13 | 15 | 18 | 18 | 19 | 20 | 18 |
| Profit before tax | 130 | 101 | 184 | 59 | 86 | 86 | 114 | 78 |
| Tax % | 27% | 25% | 24% | 25% | 26% | 26% | 22% | 26% |
| Net profit | 96 | 76 | 140 | 44 | 63 | 64 | 88 | 58 |
| EPS (₹) | 9.15 | 7.26 | 13.42 | 4.21 | 6.08 | 6.16 | 8.49 | 5.59 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Concord Biotech Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 616 | 713 | 853 | 1,017 | 1,200 | 1,055 | 1,108 |
| Operating profit | 327 | 270 | 344 | 432 | 506 | 368 | 388 |
| OPM % | 53% | 38% | 40% | 42% | 42% | 35% | 35% |
| Net profit | 235 | 175 | 240 | 308 | 372 | 259 | 273 |
| EPS (₹) | 247.44 | 183.93 | 22.95 | 29.45 | 35.52 | 24.94 | 26.32 |
TTM is the trailing twelve months to the most recent quarter.
Concord Biotech Ltd growth and returns
- 10 Years
- %
- 5 Years
- 11%
- 3 Years
- 7%
- TTM
- -7%
- 10 Years
- %
- 5 Years
- 1%
- 3 Years
- 0%
- TTM
- -22%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 17%
- 1 Year
- -10%
- 10 Years
- %
- 5 Years
- 18%
- 3 Years
- 18%
- Last Year
- 12%
Concord Biotech Ltd shareholding pattern
Promoters held 44.08% at Jun 2026, broadly unchanged since Jun 2025. FIIs 7.53% and DIIs 9.37%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% | 44.08% |
| FIIs | 8.10% | 8.33% | 9.35% | 9.10% | 8.03% | 7.58% | 7.79% | 7.53% |
| DIIs | 9.89% | 9.65% | 9.16% | 8.85% | 9.55% | 9.58% | 9.22% | 9.37% |
| Public | 37.95% | 37.93% | 37.41% | 37.94% | 38.32% | 38.75% | 38.90% | 39.04% |
| No. of shareholders | 84,298 | 82,004 | 81,219 | 82,045 | 82,650 | 81,815 | 82,249 | 83,325 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Concord Biotech Ltd events
The next scheduled event is an analyst meet on 26 Aug 2026.
- Analyst meetInvestor Conference / Group Meeting with Phillip Capital PCG
See the full results calendar for every Indian company reporting in the next 30 days.
Concord Biotech Ltd corporate filings
- We would like to inform you that the officials of the Company will be attending an Investor Conference on 26th August 2026 as per the schedule and details in the file uploaded herewith.Company Updatelow impact
Cruxal's analysis: Concord Biotech has announced that company officials will participate in an investor…
Read the full analysis - Transcript of Q1 - FY27 Earnings call held on August 03, 2026Company Updatehigh impact
Cruxal's analysis: Concord Biotech Limited reported a robust start to FY27 with Q1 revenue of INR257 crore…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Concord Biotech Ltd
Cruxal reads every Concord Biotech Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.